HSK-21542 is under clinical development by Sichuan Haisco Pharmaceutical and currently in Phase II for Unspecified Toxic Disorders. According to GlobalData, Phase II drugs for Unspecified Toxic Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HSK-21542 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HSK-21542 overview
HSK-21542 is under development for the treatment of chronic itching, uremic pruritus, post-operative pain in subjects undergoing laparoscopic surgery, urotoxicosis (unspecified toxic disorder) and chemotherapy induced nausea and vomiting. The drug candidate acts by targeting opioid kappa receptor. It is administered through intravenous bolus and oral route.
The drug candidate was under development of liver cancer.
Sichuan Haisco Pharmaceutical overview
Sichuan Haisco Pharmaceutical (Haisco) is pharmaceutical company. The company’s areas of interests include drug development, manufacturing, and sales. Haisco is headquartered in Chengdu, Sichuan, China.
For a complete picture of HSK-21542’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
